Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis. control

摘要

Antifungal prophylaxis for patients at high risk for aspergillosis is appealing due to the high morbidity and mortality of aspergillosis despite antifungal therapy (1-3). While voricon-azole is a logical option, reports of breakthrough mucormyco-sis are a cause for concern (5). To identify alternative prophylactic strategies, we utilized our novel, inhalational model of pulmonary Aspergillus fumigatus infection in neutropenic BALB/c mice (4).